News

In support of Mr. Kailian’s appointment, four of the vompany’s largest shareholders, MPM Capital, Great Point Partners, Oxford Biosciences and Venrock, have agreed to a six-month lock-up agreement.

These two new product offerings now enable rotational IVUS and FFR to operate on the same integrated Volcano s5 Imaging System as Volcano’s previous line of phased array

Preliminary data shows an increase of potency of the company’s first product candidate, DXL625 (CD20), for the prospective treatment of non-Hodgkin’s lymphoma. The study compared DXL625 with a

SkyePharma will also receive a small upfront payment. If the feasibility study is successful, full development activities will begin later in 2008. Frank Condella, CEO of SkyePharma, said:

The transaction will close on or before February 28, 2008, subject to satisfaction of customary closing conditions. Following the transaction, Green Hospital Supply’s ownership in Cytori will increase

Study 302 is a randomized, placebo-controlled, parallel-group, withdrawal-design Phase III study with an initial open-label dose titration and seven day open-label treatment period, followed by a 14-day double-blind

Merck employed four schemes to grab or maintain market share for drugs including Vioxx, Zocor, Cozaar, Fosamax, Maxalt, and Singulair, according to qui tam whistleblower lawyers Steven Cohen,

The data showed that Ardea’s lead NNRTI candidate, RDEA806, is a potent inhibitor of HIV, including the most common efavirenz resistant viruses. Oral dosing with RDEA806 achieved trough

Importantly, QuoNova’s QSB technology is an anti-virulence approach, which shows potential to prevent the consequences of infection from such drug-resistant bacteria, without inducing resistance itself. QuoNova recently demonstrated